XML 29 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Income Taxes
 9 Months Ended
Mar. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes
(11) Income Taxes
The Company’s quarterly provision for income taxes is based on the annual effective rate method. The Company’s quarterly provision for income taxes also includes the tax impact of certain unusual or infrequently occurring items, if any, including changes in judgment about valuation allowances and effects of changes in tax laws or rates, and other discrete items in the interim period in which they occur.
On August 16, 2022, the Inflation Reduction Act (the "IRA") was signed into law and contains a number of tax related provisions. The Company evaluated the provisions of the IRA and concluded that it does not have a material impact on the Company's consolidated financial statements.
The Company’s effective tax rate was 26.0% and 29.3% for the three months ended March 31, 2022 and 2023, respectively. The Company’s effective tax rate for the three months ended March 31, 2022 was higher than the federal statutory rate of 21% primarily due to an increase in non-deductible stock-based compensation under Internal Revenue Code Section 162(m), partially offset by research and development tax credits. The Company's effective tax rate for the three months ended March 31, 2023 was higher than the federal statutory rate of 21% primarily due to an increase to non-deductible stock-based compensation under Internal Revenue Code Section 162(m) and state and local income taxes.

The Company's effective tax rate was (16.4)% and 2.9% for the nine months ended March 31, 2022 and 2023, respectively. The Company's effective tax rate for the nine months ended March 31, 2022 was lower than the federal statutory rate of 21% primarily due to excess tax benefits from employee stock-based compensation, research and development tax credits, and state and local income taxes. The Company's effective tax rate for the nine months ended March 31, 2023 was lower than the federal statutory rate of 21% primarily due to excess tax benefits from employee stock-based compensation, research and development tax credits and a decrease in the valuation allowance.